ACTG and Shionogi announce progress on global phase 3 trial of novel COVID-19 oral antiviral agent S 217622
FDA has cleared the IND for S-217622, a once-daily investigational oral antiviral therapy, enabling the global phase 3 trial to ...
FDA has cleared the IND for S-217622, a once-daily investigational oral antiviral therapy, enabling the global phase 3 trial to ...
Woburn, Mass., – Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions, ...
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19 Credit: RedHill Biopharma RedHill Announces Positive Phase ...
NEW YORK and HONG KONG, February 24, 2022 -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today ...
WEST LAFAYETTE, Ind. -- GeniPhys Inc., a life sciences company focused on developing and commercializing a proprietary biopolymer technology developed in ...
UPTON, NY—Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have discovered a long-predicted magnetic state of matter called ...
Strict COVID-19 lockdown policies such as workplace closures in European cities reduced levels of air pollution and the number of ...
Although twisted sheets of double bilayer graphene have been studied extensively the past few years, there are still pieces missing ...
PHILADELPHIA — (Jan. 5, 2022) — The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 ...
Peer-reviewed / Randomised Controlled Trial / People The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection ...
Credit: Jixiang Chen The excessive consumption of fossil fuels causes serious energy and environment issues. As an ideal alternative to ...
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in ...
Oncotarget published "Impact factor and citation metrics in phase III cancer trials" which reported that a journal impact factor is often ...
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm ...
PLYMOUTH MEETING, PA — New research in the September 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds ...
PHOENIX, Ariz., Sept. 9, 2021 - The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development ...
We bring you the latest science news from best research centers and universities around the world. Check our website.
© 2023 Scienmag- Science Magazine: Latest Science News.
© 2023 Scienmag- Science Magazine: Latest Science News.